CN Patent

CN105777651A — 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途

Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2016-07-20 · 10y expired

What this patent protects

本发明涉及聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途。具体涉及聚腺苷酸二磷酸核糖转移酶(PARP)抑制剂即4‐[3‐(4‐环丙烷羰基‐哌嗪‐1‐羰基)‐4‐氟‐苄基]‐2H‐酞嗪‐1‐酮的一种新晶型、其制备方法、药物组合物和在治疗癌症中的用途，本发明所提供的新晶型重现性好，稳定易得，适合药物开发。

USPTO Abstract

本发明涉及聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途。具体涉及聚腺苷酸二磷酸核糖转移酶(PARP)抑制剂即4‐[3‐(4‐环丙烷羰基‐哌嗪‐1‐羰基)‐4‐氟‐苄基]‐2H‐酞嗪‐1‐酮的一种新晶型、其制备方法、药物组合物和在治疗癌症中的用途，本发明所提供的新晶型重现性好，稳定易得，适合药物开发。

Drugs covered by this patent

Patent Metadata

Patent number
CN105777651A
Jurisdiction
CN
Classification
—
Expires
2016-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.